Blog
RSS FeedPosted by Michael Wonder on 02 Sep 2019
Dutch experience demonstrates effective benchmarking of biosimilar use in health systems
31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...
Posted by Michael Wonder on 28 Aug 2019
Dutch health minister threatens to name and shame pharma over prices
28 August 2019 - In an unusual move, the Netherlands health minister wrote an open letter to the pharmaceutical industry ...
Posted by Michael Wonder on 28 Aug 2019
Dutch minister warns big pharma to come clean on drugs prices
27 August 2019 - Health minister Bruno Bruins has warned the pharmaceuticals industry that he considers the way drugs firms ...
Posted by Michael Wonder on 15 Jul 2019
Implementation of “coverage with evidence development” drug approval strategies found lacking
15 July 2019 - Lessons from early deployments in The Netherlands. ...
Posted by Michael Wonder on 10 May 2019
Taxpayers are funding expensive drug development, report says
10 May 2019 - The Dutch government invests tens of millions of euros every year in small biotech companies which ...
Posted by Michael Wonder on 23 Apr 2019
Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?
23 April 2019 - The Beneluxa collaboration is an initiative aimed at securing sustainable access to new medicines. ...
Posted by Michael Wonder on 12 Apr 2019
Addressing health system values in health technology assessment: the use of evidence-informed deliberative processes
8 April 2019 - Health technology assessment is increasingly used around the globe to inform resource allocation decisions. Furthermore, the importance ...
Posted by Michael Wonder on 09 Apr 2019
Conditional financing of drugs in the Netherlands: past, present, and future—results from stakeholder interviews
8 April 2019 - It is long known that managed entry agreements may offer decision makers valuable policy options to ...
Posted by Michael Wonder on 03 Apr 2019
AbbVie's massive Humira discounts are stifling Netherlands biosimilars
2 April 2019 - Could a drug's price ever be too low? That’s what some market-watchers are asking in the ...
Posted by Michael Wonder on 09 Mar 2019
Dutch join backlash at expensive drugs by making their own
8 March 2019 - In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass ...
Posted by Michael Wonder on 05 Mar 2019
Determining the comparative value of pharmaceutical risk-sharing policies in non–small cell lung cancer using real-world data
2 March 2019 - Risk-sharing arrangements can be used to mitigate uncertainty about the value of a drug by sharing the ...
Posted by Michael Wonder on 07 Feb 2019
Pharma lashes out at the Netherlands over drug pricing policies
6 November 2019 - As the Dutch government gets more aggressive about controlling the cost of medicines, the pharmaceutical industry ...
Posted by Michael Wonder on 06 Feb 2019
Novartis and Vertex battle the Netherlands government over pricing
4 February 2019 - Two large drug makers are squaring off against the Netherlands as drug pricing increasingly becomes a ...
Posted by Michael Wonder on 05 Feb 2019
Big pharma firms criticise Dutch campaign to slash drug prices
5 February 2019 - Foreign pharmaceuticals companies in the Netherlands say they are ‘concerned’ that the government is undermining the ...
Posted by Michael Wonder on 10 Jan 2019
Minister to ‘talk to Novartis’ after five-fold cancer drug price hike
10 January 2019 - Health minister Bruno Bruins is planning to talk to Swiss pharmaceuticals giant Novartis this week about ...